Identification of patients with gout: Elaboration of a questionnaire for epidemiological studies

Annals of the Rheumatic Diseases

Volumn 74, Issue 9, 2015, Pages 1684-1690

  Richette, Pascal ^a,b,c   Clerson, P ^d   Bouee S ^e   Chales G ^f   Doherty, M ^g   Flipo, R M ^h   Lambert, C ⁱ   Liote F ^a,b,c   Poiraud, T ^j   Schaeverbeke, T ^k   Bardin, T ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c INSERM   (France)

^d Orgamétrie Biostatistiques   (France)

^e CEMKA EVAL   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h UNIV LILLE   (France)

ⁱ IPSEN   (France)

^j Medical Department   (France)

^k HÔPITAL PELLEGRIN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; COLCHICINE; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; URATE;

ADULT; ADULT ONSET STILL DISEASE; AGE DISTRIBUTION; ARTHRITIS; ARTHROCENTESIS; ARTICLE; BACTERIAL ARTHRITIS; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GOUT; HEALTH CARE SURVEY; HUMAN; HUMAN TISSUE; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SELF REPORT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SPONDYLARTHRITIS; SYNOVIAL FLUID; TELEPHONE INTERVIEW; AGED; ARTHRITIS, RHEUMATOID; FRANCE; MIDDLE AGED; SPONDYLARTHROPATHIES; STATISTICAL MODEL; TELEPHONE;

ADULT; AGED; ARTHRITIS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; EPIDEMIOLOGIC STUDIES; FRANCE; GOUT; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OSTEOARTHRITIS; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY; SPONDYLARTHROPATHIES; TELEPHONE;

EID: 84942096528     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204976     Document Type: Article

References (40)

1. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12:223.
2. Richette P, Clerson P, Perissin L, et al. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis 2015;74:142-7.
3. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2011;125: 679-87. e1.
4. Teng GG, Ang LW, Saag KG, et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 2012;71:924-8.
5. Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014;73:177-82. 2013.
6. Guillemin F, Saraux A, Fardellone P, et al. Detection of cases of inflammatory rheumatic disorders: performance of a telephone questionnaire designed for use by patient interviewers. Ann Rheum Dis 2003;62:957-63.
7. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
8. Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015;74:661-7.
9. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
10. Trifiro G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis 2012;72:694-700.
11. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-41.
12. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
13. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006;8 (Suppl 1):S2.
14. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis 2010;69:1255-6.
15. Guillemin F, Saraux A, Guggenbuhl P, et al. Prevalence of rheumatoid arthritis in France: 2001.Ann Rheum Dis 2005;64:1427-30.
16. Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005;64:1431-5.
17. Roux CH, Saraux A, Mazieres B, et al. Screening for hip and knee osteoarthritis in the general population: predictive value of a questionnaire and prevalence estimates. Ann Rheum Dis 2008;67:1406-11.
18. Morvan J, Coste J, Roux CH, et al. Prevalence in two-phase surveys: accuracy of screening procedure and corrected estimates. Ann Epidemiol 2008;18:261-9.
19. Dalbeth N, Fransen J, Jansen TL, et al. New classification criteria for gout: a framework for progress. Rheumatology (Oxford) 2013;52:1748-53.
20. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
21. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64:1447-61.
22. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
23. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014;73:328-35.
24. McAdams MA, Maynard JW, Baer AN, et al. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol 2011;38:135-41.
25. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311-15.
26. O'Sullivan JB. Gout in a New England town. A prevalence study in Sudbury, Massachusetts. Ann Rheum Dis 1972;31:166-9.
27. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-103.
28. Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA 1991;266:3004-7.
29. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004;329:168-9.
30. Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011;70:563-70.
31. Janssens HJ, Fransen J, van de Lisdonk EH, et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010;170:1120-6.
32. Vazquez-Mellado J, Hernandez-Cuevas CB, Alvarez-Hernandez E, et al. The diagnostic value of the proposal for clinical gout diagnosis (CGD). Clin Rheumatol 2012;31:429-34.
33. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
34. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012;71:1839-48.
35. Becker MA, Schumacher HR Jr., Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
36. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
37. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis 2009;69:1255-6.
38. Malik A, Schumacher HR, Dinnella JE, et al. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol 2009;15:22-4.
39. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765-70.
40. O'Reilly SC, Muir KR, Doherty M. Screening for pain in knee osteoarthritis: which question? Ann Rheum Dis 1996;55:931-3.